Victory Capital Management Inc. Increases Position in Humana Inc. (NYSE:HUM)

Victory Capital Management Inc. increased its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 78.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 330,407 shares of the insurance provider's stock after purchasing an additional 145,470 shares during the period. Victory Capital Management Inc. owned 0.27% of Humana worth $87,426,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Riverview Trust Co purchased a new stake in shares of Humana in the 1st quarter valued at approximately $34,000. Garde Capital Inc. purchased a new stake in shares of Humana during the 1st quarter valued at approximately $36,000. Transce3nd LLC acquired a new position in Humana in the fourth quarter valued at approximately $38,000. Whipplewood Advisors LLC lifted its holdings in Humana by 639.1% in the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after acquiring an additional 147 shares during the last quarter. Finally, Colonial Trust Advisors grew its position in Humana by 4,500.0% in the fourth quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock worth $47,000 after acquiring an additional 180 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on HUM. Robert W. Baird lifted their target price on Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a research report on Tuesday, April 15th. Barclays set a $268.00 price objective on shares of Humana and gave the company an "equal weight" rating in a report on Thursday, June 12th. Wells Fargo & Company set a $348.00 target price on shares of Humana in a research report on Friday. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, Bank of America reduced their price target on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $282.57.

Humana Stock Down 1.6%

Shares of Humana stock traded down $3.47 during trading hours on Friday, reaching $220.08. 4,319,955 shares of the company were exchanged, compared to its average volume of 1,821,967. The firm has a market cap of $26.56 billion, a PE ratio of 15.56, a PEG ratio of 1.53 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91. Humana Inc. has a 1 year low of $207.93 and a 1 year high of $406.09. The stock's fifty day moving average is $235.46 and its 200 day moving average is $257.46.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same period in the previous year, the firm posted $7.23 EPS. Humana's revenue for the quarter was up 8.4% on a year-over-year basis. As a group, equities research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.